The first clinical trial data from 13 pancreatic cancer patients treated with LOAd703 and standard of care chemotherapy was presented at GI ASCO San Fransciso. The full study Arm 1 with 18 response evaluable patients will be presented late 2021/early 2022. Arm 2 combining LOAd703, chemotherapy and checkpoint inhibition has begun to enroll patients.
October 20, 2018
Jessica Wenthe from Uppsala University presented Lokon Pharma's research at the European Society for Medical Oncology (ESMO) in Munich and was awarded the Best Poster in the immunotherapy session. Congratulations Jessica!
April 27, 2018
The first patient has been enrolled in the LOAd703 clinical trial in Sweden, LOKON002, for the treatment of pancreatic, biliary, colorectal, and ovarian cancer.
We have been informed that individuals are receiving fraudulent job interview invitations claiming to be from Lokon Pharma. Please be aware that Lokon Pharma is not conducting any recruitment or job interviews at this time. Any message, email, or phone call offering an interview or job opportunity with our company is not legitimate.
If you receive such communication, do not respond, do not provide any personal information, and do not send any money. These contacts are part of an ongoing scam.
For your safety, please report suspicious messages to your local authorities